Tissue Inhibitor of Metalloproteinase-2
"Tissue Inhibitor of Metalloproteinase-2" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A member of the family of TISSUE INHIBITOR OF METALLOPROTEINASES. It is a 21-kDa nonglycosylated protein found in tissue fluid and is secreted as a complex with progelatinase A by human fibroblast and uncomplexed from alveolar macrophages. An overexpression of TIMP-2 has been shown to inhibit invasive and metastatic activity of tumor cells and decrease tumor growth in vivo.
Below are MeSH descriptors whose meaning is more general than "Tissue Inhibitor of Metalloproteinase-2".
Below are MeSH descriptors whose meaning is more specific than "Tissue Inhibitor of Metalloproteinase-2".
This graph shows the total number of publications written about "Tissue Inhibitor of Metalloproteinase-2" by people in this website by year, and whether "Tissue Inhibitor of Metalloproteinase-2" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
|Year||Major Topic||Minor Topic||Total|
To return to the timeline, click here.
Below are the most recent publications written about "Tissue Inhibitor of Metalloproteinase-2" by people in Profiles.
Characterising acute kidney injury: The complementary roles of biomarkers of renal stress and renal function. J Crit Care. 2022 10; 71:154066.
Serial Urinary Tissue Inhibitor of Metalloproteinase-2 and Insulin-Like Growth Factor-Binding Protein 7 and the Prognosis for Acute Kidney Injury over the Course of Critical Illness. Cardiorenal Med. 2019; 9(6):358-369.
Use of Cell Cycle Arrest Biomarkers in Conjunction With Classical Markers of Acute Kidney Injury. Crit Care Med. 2019 10; 47(10):e820-e826.
Clinical use of [TIMP-2]?[IGFBP7] biomarker testing to assess risk of acute kidney injury in critical care: guidance from an expert panel. Crit Care. 2019 06 20; 23(1):225.
Impact of Isolyte Versus 0.9% Saline on Postoperative Event of Acute Kidney Injury Assayed by Urinary [TIMP-2]???[IGFBP7] in Patients Undergoing Cardiac Surgery. J Cardiothorac Vasc Anesth. 2019 Feb; 33(2):348-356.
Risk Stratification for Acute Kidney Injury: Are Biomarkers Enough? Adv Chronic Kidney Dis. 2016 05; 23(3):167-78.
Clinical Use of the Urine Biomarker [TIMP-2]?? [IGFBP7] for?Acute Kidney Injury Risk Assessment. Am J Kidney Dis. 2016 07; 68(1):19-28.
Biomarkers in Acute Kidney Injury. Crit Care Clin. 2015 Oct; 31(4):633-48.
Furosemide Stress Test and Biomarkers for the Prediction of AKI Severity. J Am Soc Nephrol. 2015 Aug; 26(8):2023-31.
Tissue Inhibitor Metalloproteinase-2 (TIMP-2)?IGF-Binding Protein-7 (IGFBP7) Levels Are Associated with Adverse Long-Term Outcomes in Patients with AKI. J Am Soc Nephrol. 2015 Jul; 26(7):1747-54.